VERTEX PHARMACEUTICALS INC / MA (VRTX) Cash and securities
- Total cash · latest quarter (USD): Value $7.85B; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $7.85B | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $6.14B + $1.71B ≈ $7.85B |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 6.14B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 1.71B USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Cash and current securities | 7.85B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $7.85B | (m) | $6.14B | $1.71B | (m) |
| 2026-03-31 | $7.25B | (m) | $5.49B | $1.75B | (m) |
| 2025-12-31 | $6.61B | (m) | $5.08B | $1.52B | (m) |
| 2025-09-30 | $6.29B | (m) | $4.94B | $1.35B | (m) |
| 2025-06-30 | $6.38B | (m) | $4.97B | $1.41B | (m) |
| 2025-03-31 | $6.20B | (m) | $4.67B | $1.53B | (m) |
| 2024-12-31 | $6.12B | (m) | $4.57B | $1.55B | (m) |
| 2024-09-30 | $6.52B | (m) | $5.24B | $1.29B | (m) |
| 2024-06-30 | $5.80B | (m) | $4.58B | $1.22B | (m) |
| 2024-03-31 | $10.17B | (m) | $9.16B | $1.01B | (m) |
| 2023-12-31 | $11.22B | (m) | $10.37B | $849.20M | (m) |
| 2023-09-30 | $11.93B | (m) | $11.11B | $818.00M | (m) |
| 2023-06-30 | $11.24B | (m) | $10.15B | $1.09B | (m) |
| 2023-03-31 | $10.41B | (m) | $9.29B | $1.12B | (m) |
| 2022-12-31 | $10.78B | (m) | $10.50B | $274.50M | (m) |
| 2022-09-30 | $9.77B | (m) | $9.17B | $599.20M | (m) |
| 2022-06-30 | $9.25B | (m) | $8.70B | $551.20M | (m) |
| 2022-03-31 | $8.24B | (m) | $7.60B | $638.00M | (m) |
| 2021-12-31 | $7.52B | (m) | $6.79B | $729.90M | (m) |
| 2021-09-30 | $6.96B | (m) | $6.28B | $685.19M | (m) |
| 2021-06-30 | $6.71B | (m) | $6.06B | $644.32M | (m) |
| 2021-03-31 | $6.92B | (m) | $6.30B | $619.64M | (m) |
| 2020-12-31 | $6.66B | (m) | $5.99B | $670.71M | (m) |
| 2020-09-30 | $6.15B | (m) | $5.36B | $792.97M | (m) |
| 2020-06-30 | $5.45B | (m) | $4.83B | $619.44M | (m) |
| 2020-03-31 | $4.19B | (m) | $3.59B | $596.98M | (m) |
| 2019-12-31 | $3.81B | (m) | $3.11B | $698.97M | (m) |
| 2019-09-30 | $4.00B | (m) | $3.40B | $598.39M | (m) |
| 2019-06-30 | $3.95B | (m) | $3.29B | $656.54M | (m) |
| 2019-03-31 | $3.48B | (m) | $2.89B | $584.15M | (m) |
| 2018-12-31 | $3.17B | (m) | $2.65B | $518.11M | (m) |
| 2018-09-30 | $3.06B | (m) | $2.48B | $577.58M | (m) |
| 2018-06-30 | $2.77B | (m) | $2.15B | $622.40M | (m) |
| 2018-03-31 | $2.48B | (m) | $2.00B | $481.12M | (m) |
| 2017-12-31 | $2.09B | (m) | $1.67B | $423.25M | (m) |
| 2017-09-30 | $1.81B | (m) | $1.38B | $427.28M | (m) |
| 2017-06-30 | $1.67B | (m) | $1.22B | $445.52M | (m) |
| 2017-03-31 | $1.41B | (m) | $1.00B | $405.10M | (m) |
| 2016-12-31 | $1.43B | (m) | $1.18B | $250.61M | (m) |
| 2016-09-30 | $1.13B | (m) | $719.69M | $408.75M | (m) |
| 2016-06-30 | $1.07B | (m) | $605.87M | $465.57M | (m) |
| 2016-03-31 | $1.03B | (m) | $604.25M | $421.37M | (m) |
| 2015-12-31 | $1.04B | (m) | $714.77M | $327.69M | (m) |
| 2015-09-30 | $1.01B | (m) | $756.25M | $249.58M | (m) |
| 2015-06-30 | $1.02B | (m) | $870.54M | $145.91M | (m) |
| 2015-03-31 | $1.18B | (m) | $664.88M | $516.25M | (m) |
| 2014-12-31 | $1.39B | (m) | $625.26M | $761.85M | (m) |
| 2014-09-30 | $1.48B | (m) | $718.56M | $759.17M | (m) |
| 2014-06-30 | $1.22B | (m) | $420.56M | $798.60M | (m) |
| 2014-03-31 | $1.32B | (m) | $424.05M | $900.15M | (m) |
| 2013-12-31 | $1.47B | (m) | $569.30M | $895.78M | (m) |
| 2013-09-30 | $1.42B | (m) | $583.18M | $839.47M | (m) |
| 2013-06-30 | $1.43B | (m) | $531.25M | $899.45M | (m) |
| 2013-03-31 | $1.24B | (m) | $379.10M | $860.25M | (m) |
| 2012-12-31 | $1.32B | (m) | $489.41M | $831.81M | (m) |
| 2012-09-30 | $1.30B | (m) | $436.89M | $861.66M | (m) |
| 2012-06-30 | $1.22B | (m) | $454.06M | $769.27M | (m) |
| 2012-03-31 | $980.87M | (m) | $267.92M | $712.94M | (m) |
| 2011-12-31 | $968.92M | (m) | $475.32M | $493.60M | (m) |
| 2011-09-30 | $658.68M | (m) | $542.54M | $116.14M | (m) |
| 2011-06-30 | $593.49M | (m) | $458.19M | $135.30M | (m) |
| 2011-03-31 | $823.45M | (m) | $446.54M | $376.92M | (m) |
| 2010-12-31 | $1.03B | (m) | $243.20M | $788.21M | (m) |
| 2010-09-30 | $1.20B | (m) | $569.90M | $633.11M | (m) |
| 2010-06-30 | $979.14M | (m) | $337.61M | $641.54M | (m) |
| 2010-03-31 | $1.09B | (m) | $396.55M | $696.14M | (m) |
| 2009-12-31 | $1.28B | (m) | $446.66M | $838.25M | (m) |
| 2009-09-30 | (m) | (m) | $559.13M | (m) | (m) |
| 2009-06-30 | (m) | (m) | $408.95M | (m) | (m) |
| 2009-03-31 | (m) | (m) | $602.20M | (m) | (m) |
| 2008-12-31 | (m) | (m) | $389.12M | (m) | (m) |
| 2007-12-31 | (m) | (m) | $355.66M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |